3-49417892-C-T
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PM5PP3_ModeratePP5_Very_Strong
The ENST00000273588.9(AMT):c.959G>A(p.Arg320His) variant causes a missense change. The variant allele was found at a frequency of 0.0000799 in 1,613,956 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R320C) has been classified as Likely pathogenic.
Frequency
Consequence
ENST00000273588.9 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
AMT | NM_000481.4 | c.959G>A | p.Arg320His | missense_variant | 8/9 | ENST00000273588.9 | NP_000472.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
AMT | ENST00000273588.9 | c.959G>A | p.Arg320His | missense_variant | 8/9 | 1 | NM_000481.4 | ENSP00000273588 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000394 AC: 6AN: 152162Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000756 AC: 19AN: 251190Hom.: 0 AF XY: 0.0000883 AC XY: 12AN XY: 135840
GnomAD4 exome AF: 0.0000841 AC: 123AN: 1461794Hom.: 0 Cov.: 31 AF XY: 0.0000921 AC XY: 67AN XY: 727200
GnomAD4 genome AF: 0.0000394 AC: 6AN: 152162Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74320
ClinVar
Submissions by phenotype
Non-ketotic hyperglycinemia Pathogenic:6Other:1
not provided, no classification provided | literature only | GeneReviews | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Centogene AG - the Rare Disease Company | Jun 19, 2017 | - - |
Likely pathogenic, no assertion criteria provided | clinical testing | Counsyl | Nov 18, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 09, 2024 | This sequence change replaces arginine, which is basic and polar, with histidine, which is basic and polar, at codon 320 of the AMT protein (p.Arg320His). This variant is present in population databases (rs121964985, gnomAD 0.02%). This missense change has been observed in individual(s) with glycine encephalopathy with plasma and CSF Glycine levels diagnostic for this condition, as homozygous (PMID: 8005589, 10873393, 12948742). ClinVar contains an entry for this variant (Variation ID: 11979). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt AMT protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects AMT function (PMID: 23352163). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 15, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 09, 2017 | Variant summary: The AMT c.959G>A (p.Arg320His) variant involves the alteration of a conserved nucleotide, resulting in a missense substitution. 4/4 in silico tools predict a damaging outcome for this variant (SNPs&GO not captured due to low reliability index). This variant was found in the large control population database ExAC at a frequency of 0.0000745 (9/120770 control chromosomes), which does not exceed the estimated maximal expected allele frequency of a pathogenic AMT variant (0.0014049). Multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Several publications show the variant segregating with disease (e.g., Toone_MGM_2000) and additional studies provide functional data suggesting that the variant is disease causing (e.g., Swanson_Ann Neurol_2015). Taken together, this variant is classified as pathogenic. - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Sep 16, 2020 | - - |
not provided Pathogenic:5
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Feb 21, 2024 | Published functional studies demonstrate a damaging effect with loss of enzyme activity and significant reduction of glycine cleavage activity (PMID: 23352163); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 8005589, 10873393, 12948742, 27362913, 31589614, 23352163) - |
Pathogenic, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Feb 01, 2024 | AMT: PM3:Very Strong, PM2, PS3:Supporting - |
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Glycine encephalopathy 2 Pathogenic:3
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 01, 2001 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Sep 11, 2019 | - - |
Pathogenic, criteria provided, single submitter | curation | Laboratory of Medical Genetics, National & Kapodistrian University of Athens | Feb 01, 2024 | - - |
Glycine encephalopathy 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 30, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at